Respiratory medicine
August 19, 2026 · via Europe PMC
Biomarker-guided stratification of pulmonary vulnerability in juvenile dermatomyositis-associated interstitial lung disease.
Margoni A, Fotis L, Papavassiliou KA, Papavassiliou AG.
AI summary — for doctors, generated from the abstract only
This review describes emerging evidence that juvenile dermatomyositis-associated interstitial lung disease may represent an interferon-driven immune subtype, with myositis-specific autoantibody profiling currently the most clinically actionable biomarker for identifying at-risk patients.
What was studied
A narrative review summarizing emerging biomarker-based approaches for stratifying pulmonary risk in juvenile dermatomyositis-associated interstitial lung disease, covering the proposed interferon-driven immunobiological mechanism, myositis-specific autoantibodies, and cytokine and interferon-related biomarkers.
Key findings
- Interstitial lung disease associated with juvenile dermatomyositis is described as an uncommon but severe complication contributing disproportionately to morbidity and mortality, often with an insidious, initially asymptomatic presentation.
- Emerging evidence suggests this form of interstitial lung disease represents an interferon-driven immunobiological endotype, shaped by myositis-specific autoantibodies and distinct cytokine profiles.
- Among the biomarkers discussed, autoantibody profiling is described as clinically actionable now, while cytokine and interferon-related biomarkers remain investigational.
Clinical relevance
The review suggests that integrating autoantibody profiling, which is already clinically usable, with emerging cytokine and interferon pathway biomarkers, which remain investigational, could eventually enable earlier risk stratification, tailored monitoring, and more targeted therapy for children with juvenile dermatomyositis at risk of interstitial lung disease, moving practice toward proactive rather than purely reactive detection of lung damage.
Who should care
Limitations
As a narrative review, it summarizes emerging and largely investigational biomarker evidence rather than presenting new validated diagnostic or outcome data; clinical implementation of the cytokine and interferon-based biomarkers described remains to be established.
Juvenile dermatomyositis-associated lung disease may be driven by an interferon-based immune mechanism, and this review highlights autoantibody testing as a currently usable tool for identifying at-risk children, with newer biomarkers still under investigation.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Interstitial lung disease (ILD), an uncommon but severe complication of juvenile dermatomyositis (JDM), contributes disproportionately to morbidity and mortality despite its insidious and initially asymptomatic presentation. Clinical practice focuses on the detection of established lung damage, however it is vital to identify at-risk patients and provide deeper mechanistic understanding towards proactive care and clinical vigilance. Emerging evidence suggests that JDM-associated ILD represents an interferon (IFN)-driven immunobiological endotype, shaped by myositis-specific autoantibodies and distinct cytokine profiles. Within this framework, biomarkers operate across interconnected layers, from autoantibody-defined risk to pathway activation and tissue injury. While autoantibody profiling is clinically actionable, cytokine and IFN-related biomarkers remain investigational. Integrating these insights may enable earlier risk stratification, tailored monitoring, and targeted therapies.
DOI
10.1016/j.rmed.2026.109112
PMID
42617759
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed